Influenza virus vaccine live intranasal (trivalent) - MedImmune

Drug Profile

Influenza virus vaccine live intranasal (trivalent) - MedImmune

Alternative Names: CAIV-T; Fluenz; FluMist; Influenza vaccine live intranasal; Trivalent live attenuated seasonal influenza vaccine - MedImmune

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator University of Michigan
  • Developer AstraZeneca; MedImmune
  • Class Influenza virus vaccines-live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 30 Jun 2016 Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommends against the use of FluMist®
  • 31 Dec 2012 Launched for Influenza virus infections in European Union (Intranasal)
  • 01 Feb 2012 Launched for Influenza virus infections in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top